WuXi AppTec Reports Q1 Results

Seeking AlphaApr 29 09:59 ET

WuXi AppTec Co., (WUXIF) Ltd. Q1 2025 Earnings Call Transcript Summary

moomoo AIApr 29 02:38 ET · Conference Call

INNOCARE's BCL2 inhibitors are expected to be included in breakthrough therapeutic varieties.

Biological E medication time.Apr 29 00:24 ET

BEIGENE's revenue growth in 2024, narrowing losses, and core products gaining global traction.

① The company achieved a revenue of 27.214 billion yuan for the year, with a year-on-year increase of 56.19%; the net income attributable to shareholders was -4.978 billion yuan, a decrease of 17.38% from the previous year; the net income excluding non-recurring items was -5.379 billion yuan, a year-on-year decrease of 17.38%; ② The revenue share of Baiyueze and Baizean continues to expand, driving the company's revenue growth.

cls.cnApr 28 21:53 ET

WUXI APPTEC: Q1 net profit significantly increased, maintaining double-digit growth guidance for the year | Interpretations

① WUXI APPTEC's Q1 net income attributable to the parent company grew 89.1% year-on-year, mainly due to revenue growth, improved overall profitability, and the sale of WUXI XDC stocks; ② WUXI APPTEC still believes it can achieve its annual double-digit growth target.

cls.cnApr 28 09:31 ET

WUXI APPTEC: Q1 revenue of 9.655 billion yuan, a year-on-year growth of 21%, with strong performance in the Business driving significant growth.

WUXI APPTEC's first quarter of 2025: strong performance growth driven by the chemical Business, TIDES Business revenue surged by 187%. Key financial highlights...

wallstreetcnApr 28 05:15 ET